KONEXChemicals233990

Jilgyungyi

₩603▼ 5.19%2026-10-02 close

Market Cap

₩9.7B

Turnover

₩5,167,818

Volume

8,360 shares

Shares out.

16.1M

PER

—

PBR

—

EPS

—

Dividend Yield

0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Turnaround Achieved, KOSDAQ Transfer in Sight

Jilgyungyi, Korea's top-ranked feminine cleanser brand for ten consecutive years, crossed the KRW 10 billion revenue threshold in 2024 while achieving simultaneous operating and net profit turnarounds, taking concrete steps toward a planned KOSDAQ listing transfer.

1
Revenue surpassed KRW 10 billion in 2024 with simultaneous operating and net income turnarounds (MoneyToday, May 2025)
2
No.1 feminine cleanser brand reputation for 10 consecutive years; 66% repurchase rate in home shopping channel
3
Clinical trials ongoing for antibiotic-free vaginitis treatment, backed by patents registered in 7 countries globally
4
KOSDAQ listing transfer in progress — 2025 revenue target of KRW 13 billion (+30% YoY) set as milestone
5
Global feminine wash market estimated at ~USD 3.29 billion in 2025, projected at ~5.4% CAGR through 2035 (WiseGuyReports)

Business structure

Jilgyungyi (formerly Haudongcheon) was founded in October 2009 and listed on KONEX in December 2015; in November 2018 the company officially adopted its brand name as the corporate name.

The business operates through two divisions: a cosmetics division responsible for manufacturing and selling feminine hygiene products, and a pharmaceutical development division conducting patent-backed R&D.

The cosmetics division centers on six types of feminine cleansers—tablet, foam, gel, essence, spray, and tissue forms—complemented by a Y-zone whitening cream and 'Maeum,' Korea's first sanitary pad with a naturally derived corn-fiber cover.

The pharmaceutical division is conducting clinical trials for an antibiotic-free vaginitis treatment and additional gynecological therapeutics, supported by three core patents registered in seven countries including the U.S., China, Hong Kong, Russia, Australia, Mexico, and the Philippines.

Distribution is diversified across TV home shopping channels (including Hyundai Home Shopping), the company's own online store and domestic e-commerce platforms, and overseas direct channels including Amazon in the U.S. and Germany, with online and export revenue shares trending upward.

In terms of brand equity, Jilgyungyi has held the No.1 brand reputation ranking in the feminine cleanser category for ten consecutive years per the Korea Corporate Reputation Research Institute, with a 66% repurchase rate in home shopping—exceptionally high consumer loyalty for the category.

Key competitors include Uriage, Happy Bath, and Aromatica; Jilgyungyi differentiates through its proprietary solid tablet format and a lactobacillus-based mechanism that supports natural lactic acid production, internalizing a tangible product-experience moat.

Following its 2018 merger with nano molecular biotechnology firm Enpyuri, the company operates in-house R&D laboratories for both cosmetics and pharmaceuticals, progressively positioning itself as a total women's health solution provider.

The exchange sector classification is 'Chemical,' though the company is functionally a women's health specialist combining cosmetics manufacturing with clinical-stage pharmaceutical development.

Recent trends

According to a May 2025 report by MoneyToday, Jilgyungyi crossed the KRW 10 billion revenue threshold in 2024 and achieved simultaneous turnarounds in both operating income and net income—a meaningful financial inflection point.

Growth in online channels and expansion of overseas export sales were cited as the primary drivers of the 2024 improvement, with diversification into proprietary online stores and global e-commerce platforms underpinning the revenue momentum.

Management publicly set a 2025 revenue target of KRW 13 billion, representing 30% growth over the prior year, signaling continued confidence in the growth trajectory.

In 2025, the company received the Outstanding Marketing Award at the 12th Annual KONEX Grand Awards, recognizing sustained brand innovation and marketing execution.

As of June 7, 2026, the share price stands at KRW 1,693 (+0.24% day-over-day), reflecting only a modest premium to the KRW 1,250 evaluation price at the time of KONEX listing in 2015, and suggesting limited price appreciation over more than a decade.

Daily trading volume of approximately KRW 1.1 million points to extreme illiquidity—a structural characteristic of KONEX—while market capitalization is classified at 0.0 trillion KRW, placing the stock firmly in micro-cap territory.

Virtually no sell-side research coverage exists for the stock, creating significant information asymmetry and materially impairing the price-discovery function relative to KOSPI/KOSDAQ-listed peers.

Realization of the KOSDAQ transfer—the company's medium-term milestone—will hinge critically on sustaining the financial performance trajectory and the pace of ongoing innovation projects, making quarterly earnings disclosures the key monitoring events.

Outlook

The global feminine wash market is projected to grow from approximately USD 3.29 billion in 2025 to USD 5.6 billion by 2035 at a CAGR of ~5.4% (WiseGuyReports), providing a structurally favorable long-term backdrop for Jilgyungyi's core business.

Rising awareness of feminine hygiene among Korean consumers, combined with a growing preference for natural-origin and hypoallergenic ingredients, is creating favorable market conditions aligned with the company's product positioning, while the K-beauty wave opens medium-to-long-term pathways for accelerated overseas export growth.

In the near term, deepening online channel penetration and expansion via overseas direct-sales platforms such as Amazon are expected to serve as primary revenue growth engines, with achievement of the KRW 13 billion 2025 revenue target serving as the first key indicator of KOSDAQ transfer readiness.

Should the pharmaceutical division's antibiotic-free vaginitis treatment successfully complete clinical trials and gain regulatory approval, the company would unlock a therapeutics revenue stream that substantially expands its growth story beyond the cosmetics segment.

A successful KOSDAQ transfer would enhance market visibility, improve share liquidity, and potentially catalyze a valuation re-rating.

Key downside variables include clinical trial outcomes, the risk of KOSDAQ transfer schedule delays, and competitive pressure on brand market share—the trajectory of these three factors will largely determine share price direction over the next one to two years.

Bull factors

Decade-Long No.1 Brand with Exceptional Consumer Loyalty

A ten-consecutive-year No.1 brand reputation ranking in the feminine cleanser category, as measured by the Korea Corporate Reputation Research Institute, constitutes a formidable defensive moat against new competitive entrants.

A 66% repurchase rate in home shopping channels is exceptionally high for the feminine hygiene category, underpinning stable, recurring revenue from a loyal consumer base.

The proprietary solid tablet format and lactobacillus-based mechanism differentiate Jilgyungyi from competitors, internalizing a technology and user-experience gap that elevates switching costs.

A diversified product portfolio—spanning tablets, foams, gels, sprays, sanitary pads, and whitening creams—provides structural headroom for incremental cross-sell and upsell opportunities that can lift average revenue per customer.

Antibiotic-Free Drug Pipeline as a Long-Term Option Value

The pharmaceutical division is conducting clinical trials for what is positioned as the world's first antibiotic-free vaginitis treatment, with global patents registered in seven countries providing a strong first-mover advantage over potential latecomers.

Vaginitis is a prevalent condition affecting millions of Korean women annually, indicating a substantial addressable treatment market.

As concerns about antibiotic resistance continue to grow among medical communities and consumers worldwide, demand for antibiotic-free therapeutics is expected to expand meaningfully over the medium-to-long term.

A successful drug approval would add a therapeutics revenue stream on top of cosmetics income, potentially serving as a decisive catalyst for a fundamental revaluation of the company's enterprise value.

Potential Valuation Re-Rating upon KOSDAQ Transfer

Jilgyungyi is actively pursuing a KOSDAQ listing transfer on the strength of its 2024–2025 performance momentum, which, if realized, would overcome the structural liquidity limitation that defines its current KONEX status.

Inclusion on KOSDAQ would represent a comprehensive market infrastructure upgrade: access to a broader investor pool, initiation of sell-side analyst coverage, and eligibility for institutional investor accumulation.

The very process of meeting KOSDAQ listing requirements provides a verifiable benchmark for improving company fundamentals, lending credibility to the growth narrative.

A successful transfer would resolve the extreme illiquidity discount currently embedded in the share price, potentially enabling meaningful price re-discovery and a structural re-rating of equity value.

Bear factors

Extreme Illiquidity and Structural KONEX Constraints

Daily trading volume of approximately KRW 1.1 million starkly illustrates the structural liquidity constraints of the KONEX market. It is effectively impossible for institutional investors to build or unwind meaningful positions, and retail investors face difficulty executing trades at desired times.

This illiquidity impairs fair price discovery and amplifies the risk of sharp price swings on even modest order flow. Should the KOSDAQ transfer be delayed or fall through, the illiquidity condition could persist indefinitely, compounding investment risk and limiting the price-discovery function over time.

Profitability Sustainability Requires Further Validation

Having only just achieved profitability in 2024, the structural sustainability of the company's earnings improvement remains to be validated over additional reporting periods.

Intensifying competitive pressure within the feminine cleanser category and an ongoing proliferation of copycat products generate persistent brand-defense costs that weigh on margins.

Expanding R&D investment in the pharmaceutical division carries the risk of eroding profitability from the cosmetics segment, and the company's micro-cap scale limits its financial buffer against external shocks.

The operational impact of key personnel departures or management changes is also disproportionately large relative to well-established listed companies.

Clinical Development Uncertainty in Drug Pipeline

The pharmaceutical division's antibiotic-free vaginitis treatment remains at the clinical stage, and the pathway to regulatory approval—including the timeline—is subject to considerable uncertainty.

A clinical failure would make it difficult to recover resources invested in this area and would materially damage the company's long-term growth narrative.

Drug development globally is characterized by low clinical success rates and timelines that can stretch years to decades, meaning persistent R&D funding requirements could strain the company's financial position.

Progress by competitors on similar therapeutics could erode the first-mover advantage embedded in the company's patent portfolio.

Risk factors

Macro / Economic Risk

An economic downturn could drive consumers to trade down from premium feminine cleansers to lower-cost alternatives, while a sustained high-inflation, high-interest-rate environment may suppress purchase frequency and average transaction values across home shopping and online channels.

Fluctuations in the KRW/USD exchange rate directly affect the Korean won-equivalent value of export revenues, and rising raw material costs could push up manufacturing costs and compress margins.

A broad slowdown in consumer spending in key export markets—notably the U.S. and East Asia—would also constrain the company's export growth trajectory.

Regulatory Risk

Feminine cleansers are subject to the Cosmetics Act; tightening of ingredient standards or stricter advertising and labeling regulations by the Ministry of Food and Drug Safety (MFDS) would directly affect product approval processes and marketing activities.

Heightened clinical standards or revised approval requirements during the drug development process could delay the commercialization timeline and increase development costs.

Varying regulatory standards for cosmetics and pharmaceuticals across key export markets—particularly the U.S., China, and Southeast Asia—create localization compliance costs that could arise during overseas expansion.

Strengthening of personal data protection and e-commerce regulations could also raise operating costs across the online channel.

Competitive / Market Risk

Continued proliferation of copycat products exploiting similar brand names imposes persistent trademark and patent litigation costs that weigh on operating margins.

Should large cosmetics and consumer goods conglomerates launch competing products in the feminine hygiene category, their superior brand resources, distribution networks, and financial firepower pose a meaningful risk of market share erosion.

In the online channel, intensifying price competition from small emerging brands and cross-border e-commerce products could exert downward pressure on pricing and compress margin profitability.

Overall view

Jilgyungyi enters the medium term with a solid brand franchise built over more than a decade in the domestic feminine cleanser market and a meaningful financial inflection point—the 2024 return to operating and net profitability—as its foundation for a planned KOSDAQ listing transfer.

The antibiotic-free drug pipeline represents a meaningful long-term option on expanded enterprise value, and the structurally growing global feminine hygiene market provides a favorable macro backdrop.

However, daily trading volume of approximately KRW 1.1 million—a direct structural consequence of KONEX—critically impairs price discovery and makes normal market participation effectively impossible for most investors.

With profitability only just achieved, the structural sustainability of earnings improvement requires further validation through additional quarters of financial results.

Given the compounding uncertainties of clinical-stage drug development, KOSDAQ transfer schedule risk, and intensifying category competition, a Neutral stance is warranted at this juncture.

The key events for investors to monitor are the realization and timing of the KOSDAQ transfer, clinical trial progress for the antibiotic-free vaginitis treatment, and whether the company achieves its 2025 revenue target of KRW 13 billion.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 5 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.